Metabolic syndrome (MetS) and metastatic disease in patients with sporadic small intestine neuroendocrine tumour (SiNET)

#4408

Introduction: Small intestine neuroendocrine tumours (SiNETs) are rare neoplasms in which the identification of new risk factors is essential. Metabolic syndrome (MetS) is a cluster of risk factors that lead to increased mortality, especially by cardiovascular (CV) causes. MetS diagnosis is obtained with International Diabetes Federation (IDF) 2005 criteria.

Aim(s): Evaluate potential impact of MetS in a monocentric series of patients with sporadic SiNET.

Materials and methods: Retrospective analysis was conducted on patients with sporadic SiNET referred to ENETS CoE of the University Federico II of Naples between 2014 and 2024.

Conference:

Presenting Author: Minotta R

Authors: Minotta R, Liccardi A, Cannavale G, Benevento E, Di Iasi G,

Keywords: small intestine neuroendocrine tumour, metabolic syndrome, metastatic disease, survival, progression, metastasis,